Predict your next investment

Cepheid company logo
Corporation
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
cepheid.com

See what CB Insights has to offer

Founded Year

1996

Stage

Grant | Alive

Total Raised

$60.7M

Valuation

$0000 

Last Raised

$28M | 3 mos ago

Revenue

$0000 

About Cepheid

Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid previously traded under the ticker NASDAQ: CPHD.

Cepheid Headquarter Location

904 Caribbean Drive

Sunnyvale, California, 94089,

United States

408-541-4191

Latest Cepheid News

Cepheid Obtains CE Mark for Expanded Combo COVID Test

Oct 14, 2021

Save for later NEW YORK – Cepheid announced on Thursday that it has obtained the CE mark for an expanded combination COVID-19 test. The firm expects to begin shipping the new test to countries that accept the CE mark this month. The Xpert Xpress CoV-2/Flu/RSV plus is a rapid molecular diagnostic test to detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus. It obtained Emergency Use Authorization from the US Food and Drug Administration last month. In a statement, the Sunnyvale, California-based Danaher subsidiary said that the new plus version of the test adds a third gene target for SARS-CoV-2 detection in order to "meet the challenge of future viral mutations ." Cepheid said the Xpert Xpress CoV-2/Flu/RSV plus assay is designed for use on any of the firm's over 35,000 GeneXpert systems placed worldwide, with results delivered in approximately 36 minutes. "This respiratory season, healthcare providers may encounter a range of viral infections with symptoms that overlap with COVID-19, including flu A, flu B, and respiratory syncytial virus," said David Persing, Cepheid's chief medical and technology officer. "Having a fast and accurate test that is designed to detect current and future variants of the viruses that cause COVID-19 and influenza will become increasingly important," Persing added, noting that the ability to collect one sample and run a single, highly sensitive, multiplexed test "that detects and differentiates all four viruses" will provide actionable results to inform better frontline decisions within healthcare systems. Cepheid's original SARS-CoV-2 is on an FDA list of assays that could be impacted by viral variants due to point mutations in its N gene target, but the agency has noted that the test's E gene target is not affected, the overall impact is likely to be small, and that it provided the information "out of an abundance of caution."

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cepheid

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cepheid is included in 5 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

M

Medical Devices

3,583 items

https://www.amdm.org/members.html

H

Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Cepheid Patents

Cepheid has filed 138 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/25/2019

9/7/2021

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, Computing input devices

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/25/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/7/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, Computing input devices

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Cepheid Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cepheid Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.